… 27 We conducted a large, randomized, phase III study in chemotherapy-naive patients with
stage IIIB or IV NSCLC to compare the effect of docetaxel plus cisplatin (DC) and docetaxel …

… The therapeutic impact of concurrent BEV with either FOLFOX4 or XELOX chemotherapy
in the adjuvant setting was evaluated in this international, controlled phase III trial. …

Purpose This multinational, double-blind, randomized, placebo-controlled, phase III trial
assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with …

… We describe the study design for the economic evaluation of the … ) study, a multinational
phase III trial of epoprostenol (Flolan) in the treatment of congestive heart failure. In this study, …

… of 33 (15%) phase III studies showed significant differences in survival … studies have also
identified older age as a prognostic factor for response and survival [8., 9., 10.]. Phase II studies …

… Taking advantage of the new oral formulation of NVB, we decided to implement a randomised
phase III study in chemotherapy-naive patients with stage IIIB or IV NSCLC to compare the …

… Phase I and II studies of tivantinib as monotherapy or in combination with other agents in …
Although our phase III study did not meet its primary end point, the data suggest a potential …

… this large randomised multicentre phase III study was to … phase III study between 1995 and
1999. Patients meeting the eligibility criteria were randomly assigned to one of the two study …

3509 Background: The therapeutic impact of Bev plus either FOLFOX4 or XELOX in the
adjuvant setting was evaluated in the AVANT trial. First efficacy findings were presented at …

… With a view to improving options for patients, the FORUM randomized, controlled, open-label,
international, multicenter, phase III trial was designed to investigate whether preparative …